Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by wildbird1on Jun 30, 2022 3:08pm
443 Views
Post# 34794725

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Maintenance Dose

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Maintenance DosePandora... the 12 undertreated patients are confusing almost everybody, but there is something that should help us, the next Dec 2022 CR% results.

The FDA said that for BTD, TLT need 20 to 25 patients treated with 66%CR.
In Dec 2022, out of the 28 patients left(33-5), 18 will be optimized patients that have completed the 450 days(Dec 2022) + 2 CR from phase1b(3Q2021 News Letter).
And these 18 optimized patients have a CR% potential of 94.4%(3Q2021 News Letter).

These 18 optimized patients (Phase2) + 2CR( Phase1b) patients could boost the CR% by a few points(at least over the 66%CR needed for BTD).

The above could explain why TLT is talking about Jan 2023 for a BTD,TLT could be waiting for these 18 optimized patients 450 days CR% results(Dec 2022).

Dec 2022 CR% could provide us with the catalyst that we are looking for.



Pandora wrote:
Wildbird1 in a sports mode when a person sets a record but it happens to be because of some circumstance or situation that is not considered normal then the record gets an * beside it. In our case
it seems our first eight patients should be asterisked as long as they are part of the database. :-))

It seems whether we have 41 or 71 or 101 in the database then those 8 undertreated patients will reflect negatively on the total result -- although the higher the number gets the less influence, but always a little negative bump. Negligible at some point I guess.


<< Previous
Bullboard Posts
Next >>